Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE